RVNC News and Press, Revance Therapeutics Inc. From 09/24/23

2023-09-24 13:01:04 ET The growing popularity of GLP-1 weight-loss drugs may be already impacting demand for certain procedures like body contouring and dermo fillers, according to Needham’s Q3 aesthetics procedures survey. Needham asked respondents who were familiar with GLP-1 d...

2023-09-19 13:01:28 ET Gainers: Connexa Sports Technologies ( CNXA ) +170% . Davis Commodities Limited Ordinary Shares ( DTCK ) +83% . Maplebear ( CART ) +40% . Avinger ( AVGR ) +40% . Rackspace Technology ( RXT ) +37% . Elut...

2023-09-19 10:24:49 ET More on Revance Therapeutics Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn Revance's FDA Nod: Beauty, Brains, And Balance Sheets Revance Therapeutics: PDUFA Catalyst 2023 And Increased Revenues Revance wins FDA labe...

2023-09-19 10:00:54 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Hea...

Revance Therapeutics, Inc. (RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30 am ET to 12:00 pm ET. The Investor Day will include management presentations on Revance’s vision and strategy, Revance Aesthetics overview and launch progre...

2023-09-15 17:51:50 ET Summary Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains...

2023-09-15 15:00:00 ET More on the markets Key Region Of Support Sides With SPY Bullish Case Market Crosswinds And Nasdaq Looking Better Than Dow The Fed's rate-hike cycle has 'most assuredly ended' -- Lawrence Fuller Fund managers finally embrace U.S. stocks...

2023-09-15 13:02:18 ET Summary Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an opportunity to explore assets within this sector during the current period of apathy towards it. AstraZeneca's revenue was $11.42 billion in the second...

2023-09-15 11:34:06 ET Summary Revance Therapeutics' Q2 2023 revenue doubled to $58.1M YOY, driven by RHA Collection and DAXXIFY; high SG&A expenses noted. An FDA label expansion for DAXXIFY into cervical dystonia market could boost the stock, but it presents growth challenges...

2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...